Brainsway (NASDAQ:BWAY) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Brainsway (NASDAQ:BWAY) from a hold rating to a buy rating in a research report released on Saturday morning.

Several other equities analysts also recently commented on BWAY. Northland Securities increased their target price on Brainsway from $19.00 to $23.00 and gave the company an “outperform” rating in a research report on Wednesday, November 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Brainsway in a research note on Monday, December 8th. Finally, HC Wainwright lifted their target price on shares of Brainsway from $18.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Brainsway currently has an average rating of “Moderate Buy” and a consensus target price of $23.50.

Brainsway Trading Up 2.2%

Brainsway stock opened at $17.34 on Friday. The firm has a market capitalization of $339.24 million, a P/E ratio of 57.80 and a beta of 1.22. The business has a 50-day moving average of $16.22 and a 200-day moving average of $14.31. Brainsway has a 1 year low of $7.84 and a 1 year high of $18.17.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings data on Tuesday, November 11th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.03). The firm had revenue of $13.51 million for the quarter, compared to analyst estimates of $13.04 million. Brainsway had a return on equity of 9.46% and a net margin of 12.73%. Research analysts anticipate that Brainsway will post 0.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Brainsway

Hedge funds and other institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC lifted its holdings in shares of Brainsway by 7.4% during the 3rd quarter. NewEdge Advisors LLC now owns 28,629 shares of the company’s stock worth $431,000 after acquiring an additional 1,964 shares during the last quarter. Millennium Management LLC raised its position in Brainsway by 69.6% during the third quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock valued at $600,000 after purchasing an additional 16,354 shares in the last quarter. Centiva Capital LP bought a new stake in Brainsway during the third quarter worth about $181,000. Bank of America Corp DE purchased a new position in shares of Brainsway in the 3rd quarter worth about $107,000. Finally, Two Sigma Investments LP boosted its holdings in shares of Brainsway by 25.2% in the 3rd quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after purchasing an additional 20,706 shares in the last quarter. 30.11% of the stock is currently owned by institutional investors.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.